|
WO2020085504A1
(ja)
|
2018-10-26 |
2020-04-30 |
大鵬薬品工業株式会社 |
光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
|
|
JP7502337B2
(ja)
*
|
2019-05-20 |
2024-06-18 |
カリフォルニア インスティチュート オブ テクノロジー |
Ｋｒａｓ ｇ１２ｃインヒビター及びその使用
|
|
CN112552294B
(zh)
*
|
2019-09-10 |
2023-12-19 |
上海翰森生物医药科技有限公司 |
含哌嗪杂环类衍生物抑制剂、其制备方法和应用
|
|
CN112047937B
(zh)
*
|
2019-06-06 |
2023-04-07 |
劲方医药科技(上海)有限公司 |
四氢吡啶并[3,4-d]嘧啶-2(1H)-酮类化合物，其制法与医药上的用途
|
|
CN110256421A
(zh)
*
|
2019-06-26 |
2019-09-20 |
微境生物医药科技(上海)有限公司 |
Kras-g12c抑制剂
|
|
CN112390788A
(zh)
*
|
2019-08-13 |
2021-02-23 |
苏州闻天医药科技有限公司 |
一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途
|
|
CN114269735B
(zh)
*
|
2019-08-26 |
2024-02-23 |
南京创济生物医药有限公司 |
二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用
|
|
US12122787B2
(en)
|
2019-09-20 |
2024-10-22 |
Shanghai Jemincare Pharmaceuticals Co., Ltd |
Fused pyridone compound, and preparation method therefor and use thereof
|
|
UA129778C2
(uk)
|
2019-10-28 |
2025-07-30 |
Мерк Шарп Енд Доум Елелсі |
Низькомолекулярні інгібітори g12c-мутантного kras
|
|
AU2020377925A1
(en)
|
2019-11-04 |
2022-05-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202132316A
(zh)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
IL322454A
(en)
|
2019-11-04 |
2025-09-01 |
Revolution Medicines Inc |
ras inhibitors
|
|
CN114630832A
(zh)
*
|
2019-11-15 |
2022-06-14 |
四川海思科制药有限公司 |
一种嘧啶并环衍生物及其在医药上的应用
|
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
EP4067343A4
(en)
|
2019-11-29 |
2024-01-03 |
Taiho Pharmaceutical Co., Ltd. |
NEW PHENOLIC COMPOUND OR SALT THEREOF
|
|
WO2023205701A1
(en)
|
2022-04-20 |
2023-10-26 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles and uses thereof
|
|
AU2021233058B2
(en)
*
|
2020-03-12 |
2024-05-16 |
D3 Bio(Wuxi) Co., Ltd |
Pyrimidoheterocyclic compounds and application thereof
|
|
WO2021197499A1
(zh)
*
|
2020-04-03 |
2021-10-07 |
南京明德新药研发有限公司 |
八氢吡嗪并二氮杂萘啶二酮类化生物
|
|
WO2021216770A1
(en)
*
|
2020-04-22 |
2021-10-28 |
Accutar Biotechnology Inc. |
Substituted tetrahydroquinazoline compounds as kras inhibitors
|
|
WO2021244603A1
(en)
*
|
2020-06-04 |
2021-12-09 |
Shanghai Antengene Corporation Limited |
Inhibitors of kras g12c protein and uses thereof
|
|
IL299131A
(en)
|
2020-06-18 |
2023-02-01 |
Revolution Medicines Inc |
Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
|
|
WO2022040469A1
(en)
|
2020-08-19 |
2022-02-24 |
The Trustees Of The Stevens Institute Of Technology |
Spiro compounds as kras inhibitors
|
|
US20250195521A1
(en)
|
2020-09-03 |
2025-06-19 |
Revolution Medicines, Inc. |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
CA3194067A1
(en)
|
2020-09-15 |
2022-03-24 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
JP2023544450A
(ja)
|
2020-09-23 |
2023-10-23 |
エラスカ・インコーポレイテッド |
三環式ピリドン及びピリミドン
|
|
US20220112204A1
(en)
*
|
2020-10-14 |
2022-04-14 |
Accutar Biotechnology Inc. |
Substituted dihydropyranopyrimidine compounds as kras inhibitors
|
|
WO2022087624A1
(en)
*
|
2020-10-21 |
2022-04-28 |
Bioardis Llc |
Compounds as ras inhibitors and uses thereof
|
|
EP4247807A4
(en)
*
|
2020-11-23 |
2024-10-16 |
Merck Sharp & Dohme LLC |
6,7-DIHYDRO-PYRANO[2,3-D PYRIMIDINE AS INHIBITORS OF THE KRAS G12C MUTANT
|
|
US20240124478A1
(en)
*
|
2020-11-23 |
2024-04-18 |
Merck Sharp & Dohme Llc |
SPIROCYCLIC-SUBSTITUTED 6,7-DIHYDRO-PYRANO[2,3-d]PYRIMIDINE INHIBITORS OF KRAS G12C MUTANT
|
|
WO2022115439A1
(en)
*
|
2020-11-25 |
2022-06-02 |
California Institute Of Technology |
Kras g12c inhibitors and uses thereof
|
|
WO2022133345A1
(en)
|
2020-12-18 |
2022-06-23 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
CN114716436A
(zh)
*
|
2021-01-04 |
2022-07-08 |
广州百霆医药科技有限公司 |
Kras g12c突变抑制剂及其用途
|
|
US20240092803A1
(en)
*
|
2021-01-08 |
2024-03-21 |
Beigene Switzerland Gmbh |
Bridged compounds as kras g12d inhibitor and degrader and the use thereof
|
|
CN114805311B
(zh)
*
|
2021-01-21 |
2024-10-29 |
苏州亚盛药业有限公司 |
螺环茚
|
|
MX2023009037A
(es)
*
|
2021-02-01 |
2023-08-10 |
Medshine Discovery Inc |
Compuesto de pirimidopirano.
|
|
WO2022171013A1
(zh)
*
|
2021-02-09 |
2022-08-18 |
南京明德新药研发有限公司 |
四氢喹唑啉类化合物
|
|
WO2022194192A1
(zh)
*
|
2021-03-18 |
2022-09-22 |
四川科伦博泰生物医药股份有限公司 |
一类杂芳环化合物、其制备方法及用途
|
|
KR20240017811A
(ko)
|
2021-05-05 |
2024-02-08 |
레볼루션 메디슨즈, 인크. |
암의 치료를 위한 ras 억제제
|
|
TW202309052A
(zh)
|
2021-05-05 |
2023-03-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2022240971A2
(en)
*
|
2021-05-11 |
2022-11-17 |
1200 Pharma Llc |
Kras g12d inhibitors and uses thereof
|
|
CN115385937A
(zh)
*
|
2021-05-25 |
2022-11-25 |
江苏恒瑞医药股份有限公司 |
嘧啶并环烷基类化合物、其制备方法及其在医药上的应用
|
|
EP4347606A4
(en)
*
|
2021-05-28 |
2025-04-02 |
Merck Sharp & Dohme LLC |
SMALL MOLECULES INHIBITING THE G12C KRAS MUTANT
|
|
EP4389751A1
(en)
|
2021-09-03 |
2024-06-26 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
US20240400558A1
(en)
|
2021-09-09 |
2024-12-05 |
Mirati Therapeutics, Inc. |
Processes and intermediates for synthesis of adagrasib
|
|
TWI820901B
(zh)
*
|
2021-09-10 |
2023-11-01 |
大陸商德昇濟醫藥（無錫）有限公司 |
嘧啶並雜環類化合物的晶型及其製備方法
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
CN119212994A
(zh)
|
2021-12-17 |
2024-12-27 |
建新公司 |
作为shp2抑制剂的吡唑并吡嗪化合物
|
|
CN114409653A
(zh)
*
|
2021-12-31 |
2022-04-29 |
苏州闻天医药科技有限公司 |
一种桥环并嘧啶并环类化合物及其用途
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
JP2025510572A
(ja)
|
2022-03-08 |
2025-04-15 |
レボリューション メディシンズ インコーポレイテッド |
免疫不応性肺癌を治療するための方法
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2024022444A1
(zh)
|
2022-07-27 |
2024-02-01 |
江苏恒瑞医药股份有限公司 |
稠环类化合物、其制备方法及其在医药上的应用
|
|
EP4573095A1
(en)
|
2022-08-17 |
2025-06-25 |
Treeline Biosciences, Inc. |
Pyridopyrimidine kras inhibitors
|
|
CN120659773A
(zh)
|
2022-11-09 |
2025-09-16 |
锐新医药公司 |
化合物、复合物以及其制备方法和用途
|
|
AU2024241633A1
(en)
|
2023-03-30 |
2025-11-06 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
AR132338A1
(es)
|
2023-04-07 |
2025-06-18 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
CR20250420A
(es)
|
2023-04-07 |
2025-11-20 |
Revolution Medicines Inc |
Inhibidores macrocíclicos de ras
|
|
CN121464140A
(zh)
|
2023-04-14 |
2026-02-03 |
锐新医药公司 |
Ras抑制剂的结晶形式、含有其的组合物及其使用方法
|
|
CN121100123A
(zh)
|
2023-04-14 |
2025-12-09 |
锐新医药公司 |
Ras抑制剂的结晶形式
|
|
TW202508595A
(zh)
|
2023-05-04 |
2025-03-01 |
美商銳新醫藥公司 |
用於ｒａｓ相關疾病或病症之組合療法
|
|
PE20252789A1
(es)
|
2023-05-24 |
2025-12-22 |
Kumquat Biosciences Inc |
Compuestos heterociclicos y usos de estos
|
|
CN121263417A
(zh)
|
2023-06-30 |
2026-01-02 |
金橘生物科技公司 |
取代的稠合三环胺化合物及其作为ras抑制剂的用途
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
TW202528315A
(zh)
|
2023-09-21 |
2025-07-16 |
美商樹線生物科學公司 |
螺環二氫哌喃并吡啶ＫＲａｓ抑制劑
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
AU2024361909A1
(en)
|
2023-10-20 |
2026-03-26 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras proteins
|
|
WO2025171055A1
(en)
|
2024-02-06 |
2025-08-14 |
Kumquat Biosciences Inc. |
Heterocyclic conjugates and uses thereof
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025230971A1
(en)
|
2024-04-30 |
2025-11-06 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles as anticancer agents
|
|
TW202547461A
(zh)
|
2024-05-17 |
2025-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025245127A1
(en)
|
2024-05-21 |
2025-11-27 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026035947A1
(en)
|
2024-08-07 |
2026-02-12 |
Tesseract Medicines Us, Llc |
Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload
|
|
WO2026035945A1
(en)
|
2024-08-07 |
2026-02-12 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026064527A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
|
|
WO2026064520A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|